These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 12796031)

  • 1. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
    Nakagawa K; Tamura T; Negoro S; Kudoh S; Yamamoto N; Yamamoto N; Takeda K; Swaisland H; Nakatani I; Hirose M; Dong RP; Fukuoka M
    Ann Oncol; 2003 Jun; 14(6):922-30. PubMed ID: 12796031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
    Ranson M; Hammond LA; Ferry D; Kris M; Tullo A; Murray PI; Miller V; Averbuch S; Ochs J; Morris C; Feyereislova A; Swaisland H; Rowinsky EK
    J Clin Oncol; 2002 May; 20(9):2240-50. PubMed ID: 11980995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
    Herbst RS; Maddox AM; Rothenberg ML; Small EJ; Rubin EH; Baselga J; Rojo F; Hong WK; Swaisland H; Averbuch SD; Ochs J; LoRusso PM
    J Clin Oncol; 2002 Sep; 20(18):3815-25. PubMed ID: 12228201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
    Baselga J; Rischin D; Ranson M; Calvert H; Raymond E; Kieback DG; Kaye SB; Gianni L; Harris A; Bjork T; Averbuch SD; Feyereislova A; Swaisland H; Rojo F; Albanell J
    J Clin Oncol; 2002 Nov; 20(21):4292-302. PubMed ID: 12409327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
    Von Pawel J
    Bull Cancer; 2004 May; 91(5):E70-6. PubMed ID: 15582898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib, a novel, orally administered agent for the treatment of cancer.
    Ranson M; Wardell S
    J Clin Pharm Ther; 2004 Apr; 29(2):95-103. PubMed ID: 15068398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
    Cohen MH; Williams GA; Sridhara R; Chen G; McGuinn WD; Morse D; Abraham S; Rahman A; Liang C; Lostritto R; Baird A; Pazdur R
    Clin Cancer Res; 2004 Feb; 10(4):1212-8. PubMed ID: 14977817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
    Cantarini MV; McFarquhar T; Smith RP; Bailey C; Marshall AL
    Clin Ther; 2004 Oct; 26(10):1630-6. PubMed ID: 15598479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
    Daw NC; Furman WL; Stewart CF; Iacono LC; Krailo M; Bernstein ML; Dancey JE; Speights RA; Blaney SM; Croop JM; Reaman GH; Adamson PC;
    J Clin Oncol; 2005 Sep; 23(25):6172-80. PubMed ID: 16135484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
    Zhang L; Li S; Zhang Y; Zhan J; Zou BY; Smith R; Martin PD; Jiang Y; Liao H; Guan Z
    Clin Ther; 2011 Mar; 33(3):315-27. PubMed ID: 21600385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
    Santoro A; Cavina R; Latteri F; Zucali PA; Ginanni V; Campagnoli E; Ferrari B; Morenghi E; Pedicini V; Roncalli M; Alloisio M; Ravasi G; Soto Parra HJ
    Ann Oncol; 2004 Jan; 15(1):33-7. PubMed ID: 14679116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I dose-escalation and pharmacokinetic trial of lapatinib (GW572016), a selective oral dual inhibitor of ErbB-1 and -2 tyrosine kinases, in Japanese patients with solid tumors.
    Nakagawa K; Minami H; Kanezaki M; Mukaiyama A; Minamide Y; Uejima H; Kurata T; Nogami T; Kawada K; Mukai H; Sasaki Y; Fukuoka M
    Jpn J Clin Oncol; 2009 Feb; 39(2):116-23. PubMed ID: 19052038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
    Jänne PA; Boss DS; Camidge DR; Britten CD; Engelman JA; Garon EB; Guo F; Wong S; Liang J; Letrent S; Millham R; Taylor I; Eckhardt SG; Schellens JH
    Clin Cancer Res; 2011 Mar; 17(5):1131-9. PubMed ID: 21220471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose clinical pharmacokinetic studies of gefitinib.
    Swaisland HC; Smith RP; Laight A; Kerr DJ; Ranson M; Wilder-Smith CH; Duvauchelle T
    Clin Pharmacokinet; 2005; 44(11):1165-77. PubMed ID: 16231967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib (Iressa) trials in non-small cell lung cancer.
    Johnson DH
    Lung Cancer; 2003 Aug; 41 Suppl 1():S23-8. PubMed ID: 12867059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
    Mu XL; Li LY; Zhang XT; Wang SL; Wang MZ
    BMC Cancer; 2004 Aug; 4():51. PubMed ID: 15318946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
    Furman WL; Navid F; Daw NC; McCarville MB; McGregor LM; Spunt SL; Rodriguez-Galindo C; Panetta JC; Crews KR; Wu J; Gajjar AJ; Houghton PJ; Santana VM; Stewart CF
    J Clin Oncol; 2009 Sep; 27(27):4599-604. PubMed ID: 19687340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
    Ahn MJ; Kim DW; Cho BC; Kim SW; Lee JS; Ahn JS; Kim TM; Lin CC; Kim HR; John T; Kao S; Goldman JW; Su WC; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; Yang JC
    Lancet Respir Med; 2017 Nov; 5(11):891-902. PubMed ID: 29056570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
    Gross ME; Leichman L; Lowe ES; Swaisland A; Agus DB
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):273-80. PubMed ID: 22002543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.